The increase in price target by a reputable analyst like Morgan Stanley suggests a positive outlook on NeuroPace's stock, which could lead to increased investor confidence and a potential short-term rise in the stock price. The Equal-Weight rating indicates that the stock is expected to perform in line with the sector or the overall market, but the raised target price implies that the analyst sees more upside potential than before.